Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls.
Journal
Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
13
05
2020
accepted:
30
06
2020
pubmed:
13
8
2020
medline:
30
3
2021
entrez:
13
8
2020
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA)-based positron-emission tomography (PET)-computed tomography (CT) has shown great promise in prostate cancer imaging. This technique has demonstrated particular utility in the staging of high-risk primary cancer and in the localisation of recurrent disease. The use of fluorine-18 PSMA-1007 is advantageous, as it is excreted via the hepatobiliary system rather than urinary and the longer half-life of fluorine-18 compared to gallium tracers, allows for PSMA imaging in centres without a gallium generator. However, imaging with this tracer is not without flaws and areas of ambiguity remain. In this article, the biodistribution, clinical indications, and pearls of
Identifiants
pubmed: 32782128
pii: S0009-9260(20)30273-7
doi: 10.1016/j.crad.2020.06.031
pii:
doi:
Substances chimiques
Fluorine Radioisotopes
0
Radiopharmaceuticals
0
Prostate-Specific Antigen
EC 3.4.21.77
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-913Informations de copyright
Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.